SRR1500617
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.428
- COAGULATION+0.367
- TNFA_SIGNALING_VIA_NFKB+0.364
- INFLAMMATORY_RESPONSE+0.355
- PANCREAS_BETA_CELLS+0.324
- ALLOGRAFT_REJECTION+0.281
- IL6_JAK_STAT3_SIGNALING+0.245
- XENOBIOTIC_METABOLISM+0.213
- APICAL_SURFACE+0.175
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.175
Top 10 suppressed
- MYC_TARGETS_V1-0.609
- PROTEIN_SECRETION-0.562
- MYC_TARGETS_V2-0.481
- UNFOLDED_PROTEIN_RESPONSE-0.471
- DNA_REPAIR-0.464
- MITOTIC_SPINDLE-0.448
- OXIDATIVE_PHOSPHORYLATION-0.446
- ANDROGEN_RESPONSE-0.401
- MTORC1_SIGNALING-0.395
- E2F_TARGETS-0.373
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1418604 | GTEX | — | 0.968 |
| 2 | SRR1476614 | GTEX | — | 0.955 |
| 3 | SRR1459423 | GTEX | — | 0.949 |
| 4 | SRR1103048 | GTEX | — | 0.948 |
| 5 | SRR1432765 | GTEX | — | 0.946 |
| 6 | TCGA-95-A4VP-01A-21R-A262-07 | — | cohortA3 | 0.944 |
| 7 | SRR1352554 | GTEX | — | 0.943 |
| 8 | SRR1389348 | GTEX | — | 0.942 |
| 9 | SRR1392725 | GTEX | — | 0.942 |
| 10 | SRR1331511 | GTEX | — | 0.942 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.428 | Remibrutinib | — uncovered |
| COAGULATION | 0.367 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.364 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.355 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.324 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.281 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.245 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.213 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.175 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.175 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.173 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.133 | Idelalisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.108 | Inavolisib | — uncovered |
| COMPLEMENT | 0.098 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.077 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.044 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.038 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.037 | Inavolisib | — uncovered |
| APOPTOSIS | 0.032 | Idelalisib | — uncovered |